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ABSTRACT
Background The evolution of the techniques used in the intensive care setting over the past decades has led
on one side to better survival rates in patients with acute conditions and severely impaired vital functions. On
the other side, it has resulted in a growing number of patients who survive an acute event, but who then
become dependent on one or more life support techniques. Such patients are called chronically critically ill
patients.
Materials & Methods No absolute definition of the disease is currently available, although most patients are
characterized by the need for prolonged mechanical ventilation. Mortality rates are still high even after dismissal
from intensive care unit (ICU) and transfer to specialized rehabilitation care settings.
Results In recent years, some studies have tried to clarify the pathophysiological characteristics underlying
chronic critical illness (CCI), a disease that is also characterized by severe endocrine and inflammatory impair-
ments, partly accounting for the almost constant set of symptoms.
Discussion Currently, no specific treatment is available. However, a strategic early therapeutic approach on ICU
admission might try to prevent the progress of the acute disease towards chronic critical illness.
Keywords chronic critical illness, mechanical ventilation, systemic inflammation, wasting syndrome.
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Clinical case overview
A 60-year-old man was admitted to ICU for acute respiratory
failure secondary to ARDS. The patient underwent
mechanical ventilation via endotracheal tube with protective
strategy, and started antibiotics and steroids intravenously.
Chest CT scan showed diffuse bilateral ground glass with
atelectasis in dorsal areas. After 10 days of treatment, due to
the persistence of severe respiratory failure, a tracheostomy
was performed. The patient’s clinical conditions and gas
exchange improved in the following days, but an evolution
towards lung fibrosis was radiographically detected. Thirty
days after admission, the patient presented with severe
muscle wasting, while weaning from mechanical ventilation
was difficult due to the onset of severe alveolar hypoventi-
lation during spontaneous breathing trial. Blood tests showed
hyperglycaemia requiring insulin administration at high
doses. Furthermore, the patient experienced periods of
delirium, treated with sedatives and antipsychotics, forcing
the patient to prolonged immobility. After 40 days of hospi-
talization in ICU, the patient was transferred to a weaning
centre.
What is the patient’s prognosis? Will he recover
functional autonomy?
Intensive care units (ICUs) were devised to artificially maintain
vital functions that were previously impaired due to an acute
condition, while the patient is recovering from the disease [1,2].
Their set of treatments is quite commonly applied to a popu-
lation presenting with an increasingly advanced average age
and with multimorbidities [3,4]. Although significantly
achieving a reduction in mortality rates, ICUs also led to a
growth in the number of patients who overcome the acute stage
of the disease, but who become dependent for a long time on
techniques supporting one or more vital functions, therefore
becoming ‘chronically critically ill’.
Definition and epidemiology
The definition of ‘chronically critically ill patient’ was coined
by Girard and Raffin in 1985, in an article describing a set of
patients who remained dependent on vital support treat-
ments after an acute critical disease requiring admission to
ICU [5].
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Due to the clinical difficulty in identifying the progression
from the acute phase of the disease to its becoming chronically
critical, an absolute definition of chronic critical illness is cur-
rently unavailable. However, as prolonged mechanical venti-
lation is required by the vast majority of the affected patients,
this feature is a primary indicator for the definition of chronic
critical illness [6].‘Prolonged mechanical ventilation’ has been
defined as the need for ventilatory support for more than 21
consecutive days for at least 6 h per day [7].
Another element for the identification of these patients is the
need to perform tracheotomy at ICU, when the patient requires
prolonged mechanical ventilation and on the basis of a clinical
judgment regarding patient stability. However, these defini-
tions are limited, take into account the need for prolonged
mechanical ventilation and fail to cover the entire spectrum of
conditions that fall into this syndrome.
Epidemiologically, chronic critical illness has become a rele-
vant emerging issue: some studies report that up to 5–10% of
patients admitted to ICU require prolonged mechanical venti-
lation, with 100 000 patients assessed in the US only [8].
Around 30–50% of chronically critically ill patients can be dis-
charged from ICU or other acute care settings without venti-
latory support, although comorbidities, weak functional
compensation and common infectious complications are the
main factors affecting prognosis [9,10]. One-year mortality is
assessed to be around 48–68%, and some studies report that
only 10% of chronically critically ill patients achieve functional
autonomy and live at their home at 1 year after the onset of the
acute condition requiring admission to ICU [11–13].
Clinical features
Although the main marker in patients with chronic critical ill-
ness is respiratory failure requiring prolonged mechanical
ventilation, other clinical features are always present and out-
line a specific clinical syndrome (Fig. 1). Endocrine alterations
and prolonged inflammation cause myopathy, neuropathy and
changes in body composition including loss of lean body mass.
Neurological changes often occur such as coma or delirium
extending over a long period. These patients present with dif-
ferent levels of nutritional deficiency, while prolonged immo-
bility and enhanced susceptibility to infections are extremely
common.
Physiopathological mechanisms
Currently, no explanation is available on the reason why
among patients with similar severity and requiring intensive
treatment some experience a rapid recovery of vital functions
while others become chronically critically ill. Moreover, there
are no biomarkers that can assist in predicting the development
of this condition. Risk factors for chronic critical illness include
old age, comorbidities and type of disease, while the most fre-
quent acute conditions involved are sepsis and ARDS (acute
respiratory distress syndrome), both characterized by an
immune response triggering a significant systemic inflamma-
tion [14]. The progress from acute disease to chronic critical
illness leads to significant changes in endocrine response,
partly accounting for the clinical syndrome present in such
patients (Fig. 2). Systemic inflammation and endocrine
derangement are related with malnutrition, brain dysfunction
and muscle weakness.
Systemic inflammation
Chronic critical illness can also be defined as a persistent sys-
temic inflammation triggered by an initial insult. The progress
from an acute condition into chronic critical illness may be
favoured by two factors: (i) inflammation insult severity during
acute phase and (ii) missed resolution of inflammation. For
example, ARDS patients present with a significant increase in
TNF-a, IL-1b, IL-6 and IL-8 plasma levels.
Patients presenting with higher inflammation levels at dis-
ease onset and persistent blood cytokine increase during its
course show worse prognosis and higher incidence of multiple
organ failure [15]. This group of patients, whose survival
depends on life support techniques, requires prolonged
mechanical ventilation and therefore faces an increased risk of
developing chronic critical illness. Old age, as a risk factor, is
associated with the chronic increase in the levels of some
inflammatory markers, such as IL-6, TNF, IL-1 receptor antag-
onist and CPR, on which an acute condition may trigger and
amplify an inflammatory response [16].
The process leading to the resolution of inflammation is
not a passive mechanism, as it involves a complex biological
Figure 1 Clinical features of chronic critical illness
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programme requiring the function of specific mediators and
cells. The main stages involved are as follows: (i) clearance of
disease triggering event, (ii) apoptosis of polymorphonucle-
ates and efferocytosis with tissue macrophages, (iii) anti-
inflammatory cytokine release (TGF-b, IL10), and (iv) removal
of macrophages from the body or apoptosis [17]. This com-
plex mechanism is regulated by over 80 genes whose muta-
tion, in animal models, can develop persistent spontaneous
inflammation even without any pathogen trigger [18]. The
impaired regulation of the processes aimed at limiting dam-
age associated with inflammation might be involved in the
progression of the acute critical disease into chronic critical
illness.
Despite the fact that the persistence of inflammation is
probably a major cause of development of a chronic critical
illness, even the presence of a low-inflammatory state and a
subsequent immunosuppressive phase following sepsis may
play a role [19]. After an initial cytokine storm, some patients
experience an immunosuppression phase characterized by
apoptosis and cell loss of the innate and adaptive immune
system involving CD4, CD8, B-type and dendritic cells [20].
This condition of immuno-paralysis can last longer and
increases host susceptibility to infections, thus promoting the
persistence of critical illness.
Endocrine alterations
Endocrinological abnormalities have been recognised for
patients with acute critical illness, but not for patients with
chronic critical illness.
During the acute stage of a critical disease, a complex neuro-
immune response is activated, most presumably aimed at
providing immediate availability of energy substrates for the
cellular processes required to maintain vital functions [21]
(Table 1). The hypothalamic–pituitary axis activation promotes
lipolysis, proteolysis and gluconeogenesis, while the anabolic
process is temporarily suspended. During the first hours after
an acute insult, circulating growth hormone (GH) levels
increase secondary to the rise in secretion peaks and in pulse
frequency of pituitary gland. This central activation is associ-
ated with a reduction in serum concentration of effector pro-
teins IGF-I (insulin-like growth factor-I), IGFBP3 (IGF binding
protein 3) and ALS (acid-labile subunit). An acquired peripheral
GH resistance is then established, inhibiting anabolic and acti-
vating catabolic processes. Moreover, neuroendocrine response
Figure 2 Pathophysiology of progression from acute disease to chronic critical illness. The acute disease is characterized by the
presence of a significant inflammatory response and the activation of the hypothalamic–pituitary axis, with the purpose of delaying
the anabolism and increase the catabolism to make available the energy substrates. The resolution of the inflammatory process
results in healing and restoration of normal neuroendocrine activity. If inflammation fails to resolve, the persistent disease leads to
the development of an exhaustion of the neuroendocrine response with the appearance of chronic critical illness.
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to acute stress results in hypercortisolism caused by the
increased secretion of ACTH (adrenocorticotropic hormone) from
anterior pituitary, which in turn is stimulated by the hypotha-
lamic factor called CRH (corticotropin-releasing hormone). The
rise in cortisol levels, not only contributes to the availability of
energy substrates, but it also causes a positive hemodynamic
effect through intravascular fluid retention and increase in
inotropic and vasopressure response to catecholamines and
angiotensin II. Moreover, cortisol has an anti-inflammatory
effect, which might be involved in the mechanisms aimed at
limiting the damage produced by the acute triggering event.
During sepsis, a relative adrenal insufficiency may develop:
in such condition, despite an increase in ACTH, cortisol pro-
duction is insufficient to maintain hemodynamic stability [22].
The most common clinical feature is the appearance of
hypotension refractory to fluid challenge and requiring the use
of vasopressors [23].
Diagnostic criteria for this condition are controversial, but the
most common method is the detection of an insufficient
increase in plasma cortisol (<9 lg/dL) after stimulation with a
bolus of 250 lg of ACTH [21].
The hypothalamic–pituitary–thyroid axis is also activated
with a sharp but short rise in TSH and T4 levels paired with T3
reduction, which is presumably secondary to the drop in T4 to
T3 conversion in peripheral organs. The latter changes might be
interpreted as an attempt to curb tissue energy expenditure to
face reduced substrate availability.
While such process may be considered as the Darwinian
response to an acute stress, the chronic process of a critical ill-
ness involves significant changes in neuroendocrine response.
Evolution has not provided our nervous and endocrine system
with the ability to withstand a prolonged inflammation
requiring artificial life support.
The main consequence to this condition is a reduction in
pulsatile secretion of anterior pituitary hormones associated
with the so-called wasting syndrome [24].
Pulsatile secretion of GH is reduced and correlates with the
lower circulating levels of IGF-I and of binding proteins
(IGFBP-3, ALS, IGFBP-5). This hyposomatotrophism also
accounts for the occurrence of the waste syndrome usually
detected in these patients. Serum ACTH levels fall sharply
while cortisol levels remain high. This typical dissociation in
the chronic stage shows that cortisol production is not ACTH
dependent, but that it is probably triggered by other factors
such as cytokine cascade secondary to persistent inflammation.
Another factor promoting persistently high cortisol levels is the
reduction in cortisol metabolism regardless of the inflammatory
condition in the patient [25]. The persistent increase in cortisol
levels may play a decisive role in the onset of some typical
clinical features of the chronically critically ill patient: (i)
increased susceptibility to infections, (ii) reduced wound-heal-
ing capacity and (iii) onset of myopathy.
The prolonged absence of ACTH stimulation during chronic
critical illness may in the long-term lead to adrenal gland
atrophy and cause symptomatic adrenal insufficiency, an event
with a 20-fold higher incidence in patients admitted to ICU for
more than 14 consecutive days.
A reduction in pulsatile TSH secretion is also detected in the
hypothalamic–pituitary–thyroid axis, resulting in low plasma
levels of specific hormones (T3, T4). T3 plasma levels inversely
correlate with muscle weakness and bone loss markers.
Another endocrine impairment is hyperglycaemia secondary
to the response to acute stress, resulting from the activation of
gluconeogenesis and from the reduction of insulin sensitivity in
peripheral tissues [26]. The onset of stress-induced hypergly-
caemia is influenced by a number of clinical factors, such as
age, glucose tolerance, presence of comorbidities, need for
parenteral nutrition, obesity and severity of the underlying
disease. Once hyperglycaemia is present, it may persist even in
the course of chronic critical illness, involving an increased risk
of mortality [27].
Malnutrition
One of the characteristics found in chronic critical illness is a
state of malnutrition associated with chronic inflammation and
hormonal changes. The increase in proteolysis and the reduced
Table 1 Endocrine abnormalities in acute and chronic critical
illness
Hormone
Acute critical
illness
Chronic critical
illness
Somatotropic axis
Pulsatile GH
secretion
↑ ↓
GHBP ↓ ↑
IGF-I ↓ ↓↓
ALS ↓ ↓↓
IGFBP-3 ↓ ↓↓
Thyroid axis
Pulsatile TSH
secretion
↑ ↓
T4 ↑ ↓
T3 ↓ ↓↓
Adrenal axis
ACTH ↑ ↓
Cortisol ↑↑ ↑↓*
*Adrenocortical insufficiency.
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hepatic synthesis of albumin result in hypoalbuminaemia and
in a hypo-oncotic state [28–30]. This condition resembles the
typical wet malnutrition of children in African countries
(kwashiorkor) that occurs when protein malnutrition predom-
inates compared to the reduction in total calor7ies. Therapies
used in ICU, especially fluid resuscitation, can worsen this
condition and promote anasarca.
In addition, protein wasting causes weakness of the skeletal
muscles, increases the risk of hospital infections (i.e. deficiency
in wound healing) and prolongs hospitalization [31].
Refeeding by enteral route supplies protein and energy
required for cellular and organ functions, but also improves
immune function through hormonal changes. In particular, the
secretion of glucagon-like peptide-1 (GLP-1) by L cells of the
distal ileum in presence of food [32] is able to stimulate insulin
secretion, slow down gastric emptying and influence the cell-
mediated immunity [33,34,35]. A recent clinical trial showed
that early enteral nutrition can improve cell-mediated immu-
nity via different routes by the secretion of GLP-1 and is asso-
ciated with positive clinical effects [36].
Brain dysfunction
Brain dysfunction is another common condition complicating
the course of a critical illness in ICU, presenting with coma
and delirium. Studies analysing patients with acute critical
illness showed that brain dysfunction is associated with
increased mortality and long-term cognitive impairment in
survivors [37–41].
Even during chronic critical illness, brain dysfunction
appears to affect 29–69% of patients, whereas its prognostic
impact is less clear [42–45]. Ten to 77% of patients who survive
present with long-term brain dysfunction and different degrees
of cognitive impairment [46,47]. Risk factors for developing
long-term brain dysfunction include advanced age, high grav-
ity score and the presence of cerebral dysfunction in the period
of hospital care for chronic critical illness [48].
The pathophysiology of cerebral dysfunction appears to be
multifactorial. Delirium seems to be related to the imbalance
between dopamine production (which increases neuronal
excitability) and acetylcholine depletion (which has an inhibi-
tory effect) in controlling cognitive functions [49,50]. During a
critical illness, cytokines and chemokines produced by the
systemic inflammation may be able to cross the blood–brain
barrier, as demonstrated by studies in animal model [51]. These
mediators can promote brain dysfunction through endothelial
damage, impaired cerebral vascular permeability, formation of
microaggregates, reduction of cerebral blood flow and alter-
ation of neurotransmitters’ synthesis [52]. A recent study
enrolled 147 patients in ICU and showed that in patients with
worse systemic endothelial function acute brain dysfunction
persisted for longer [53]. Among the other mechanisms which
may contribute to the development of delirium, the increase in
brain uptake of some amino acids such as tryptophan and
phenylalanine (precursors in the synthesis of dopamine) is
most likely [54].
Finally, exposure to analgesics and sedatives and/or sleep
deprivation may also play a role in precipitating delirium.
Some studies have identified the use of meperidine, midazolam
and lorazepam as potential risk for developing delirium
[50–55].
Muscle weakness
Survivors to acute illness in ICU often develop neuropathy and
myopathy. These conditions are common in chronic critical
illness, limiting mobilization and weaning from mechanical
ventilation [56]. Two main recognized clinical conditions cause
muscle weakness in these patients: (i) critical illness polyneu-
ropathy (CIP) and (ii) critical illness myopathy (CIM).
CIP is a distal axonal sensory-motor polyneuropathy, which
can affect the limbs but also respiratory muscles [57]. Electro-
physiological studies show a reduction in the compound
muscle action potential (CMAP), while the sensory nerve action
potential (SNAP) has almost normal conduction velocity [56].
Pathophysiology is not known, but it is assumed that axonal
injury derives from a microvascular dysfunction and impair-
ment in the blood–nerve barrier (BNB) [57] leading inflamma-
tory mediators to produce the neuropathy damage [58].
CIM is an acute primary myopathy presenting with muscle
atrophy, and a characteristic pattern of selective loss of myosin
on muscle biopsy [56]. The cause is the imbalance between
muscle protein breakdown and synthesis determined by mul-
tifactorial events during acute illness. The molecular basis of
muscle atrophy involves activation of the ubiquitin–protea-
some (UPS) and autophagy–lysosome systems [59]. Activation
of these two systems is coordinated by the family of tran-
scription factors forkhead box O (FoxO) that is translocated into
the nucleus and induces transcription of target genes during
conditions such as muscular inactivity, inflammation and
malnutrition [57,60]. Interestingly, studies on animals showed
that the activation of autophagy results in muscle atrophy, but
also that the complete suppression of this pathway leads to
muscle degeneration through accumulation of protein aggre-
gates, mitochondrial abnormalities and enhanced oxidative
stress [61]. Therefore, autophagy must be finely adjusted to
maintain appropriate muscle mass.
Several studies show that there is significant overlap between
CIP and CIM, and therefore, the term critical illness polyneu-
romyopathy (CIPNM) was coined to better underline the
coexistence of both neuropathy and myopathy [62]. Drugs
(corticosteroids, neuromuscular blocking agents), high blood
glucose levels, immobility and deep sedation represent risk
factors for developing CIPNM [56].
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Prevention and treatment
To date, no specific treatment for chronic critical illness is
available. The attempts made to activate the hypothalamic–
pituitary axis with hormone treatment can reduce hyper-
catabolism and increase anabolism, but they have shown no
clear impact on prognosis [63,64]. Conversely, the imple-
mentation on ICU admission of a combination of strategies
aimed at preventing the progression of an acute disease into
chronic critical illness has proved to be fundamental. Such
procedures are aimed at reducing systemic inflammation,
treating endocrine alterations and preventing mechanical
ventilation-induced diaphragmatic dysfunction.
With reference to systemic inflammation, protective
mechanical ventilation, that is with lower tidal volumes (6 mL/
kg) and lower pressures (plateau pressure lower than
30 cmH2O), compared to standard mechanical ventilation has
proved to reduce the concentration of pulmonary and systemic
inflammatory mediators during acute respiratory distress syn-
drome (ARDS) [65]. Early rehabilitation therapy in patients
undergoing mechanical ventilation showed to reduce systemic
cytokine levels, increase the number of ventilator-free days,
shorten the duration of delirium and promote the recovery of
functional independence [66,67].
Among endocrine alterations, the control of stress-induced
hyperglycaemia is one of the main therapeutic goals in case of
acute critical illness requiring ICU admission. Insulin therapy
for hyperglycaemia with a tight glucose monitoring can reduce
the incidence of mortality, renal failure, sepsis and polyneu-
ropathy (CIPNM) and can also facilitate weaning from
mechanical ventilation [68,69]. However, such positive effects
are offset by an increase in mortality in case of onset of severe
hypoglycemia [70].
One of the primary causes of progression towards chronic
critical illness is mechanical ventilation-induced diaphragm
dysfunction. Human studies show that controlled mechanical
ventilation, even after a few days, may lead to significant fibre
atrophy in both fast and slow muscle fibres of the diaphragm,
associated with signs of oxidative stress and increase in muscle
proteolysis [71]. After six consecutive days of controlled inva-
sive mechanical ventilation, the pressure generated by the
diaphragm during phrenic nerve stimulation drops by 30%
[72]. Therefore, the implementation of strategies aiming at
reducing as much as possible the days requiring mechanical
ventilation is paramount to prevent the onset of diaphragm
dysfunction. A randomized and controlled study performed in
patients undergoing invasive mechanical ventilation evidenced
that daily sedative interruption associated with spontaneous
breathing cycles can reduce the total number of ventilator days
and increase the chances of dismissal from ICU [73].
Association of early rehabilitation treatments, daily sedative
interruption and application of spontaneous breathing trials
aimed at early weaning from mechanical ventilation are useful
strategies to try to prevent an evolution towards chronic critical
illness.
Nutritional support can play a role both in the prevention
and treatment of chronic critical illness, although currently no
data are available on this specific group of patients.
The evidence regarding nutritional support in ICU suggests
that in patients with preserved gastrointestinal tract, enteral
nutrition is to be preferred, providing trophic stimulus to
enterocytes, reducing bacterial translocation and determining
the secretion of hormones [28]. Moreover, compared to par-
enteral nutrition in critical patients, early (48 h after admission
to ICU) enteral nutrition has shown to reduce septic compli-
cations, improve the course of the disease and reduce the length
of hospital stay [74,75], thus suggesting a preventive role in the
development of chronic critical illness.
Another issue related to the nutritional support in chronic
critical illness is the global amount of protein and calories to be
administered to the patient [76]. Opinion of experts suggests to
administer a sufficient amount of protein (from 10–12 to 12–
15 g/kg/day, but up to 2 g/kg/day in subjects with renal
failure, ulcers or conditions associated with loss of nitrogen) to
compensate hypercatabolic state [28].
Regarding calories intake, both under- and over-feeding are
associated with poor prognosis in patients admitted to ICU [77–
79]. Experts recommend to set to 20–25 kcal/kg dry adjusted
weight/day to provide sufficient energy. Due to the lack of
specific data on this topic and the complex nutritional man-
agement, the presence of a nutrition specialist is recommended
in the healthcare team.
Delirium is another frequent condition in ICU patients, rep-
resenting a significant burden both to the patient and to the
healthcare system. The management of this condition in chronic
critical illness is one of the most problematic issues for clini-
cians. One of the goals is to reduce as much as possible the
administration of sedatives such as midazolam and lorazepam,
which are one of the main risk factors for delirium [80].
Haloperidol is the first line drug for the management of agita-
tion and delirium, and it is related with lower hospital mor-
tality in mechanically ventilated patients [81]. As an alternative,
olanzapine was found to have comparable efficacy of
haloperidol in controlling delirium, but with fewer extrapyra-
midal side effects [82].
Ethical issue
Chronic critical illness also poses important ethical issues: what
is the dividing line between care and futility? When should
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decisions on the suspension of life support be considered?
When should we qualify and quantify quality of life as unac-
ceptable and when should palliative care be considered as
mandatory?
Patients at this stage are often unable to decide on their fate,
while family members are often emotionally involved. There-
fore, medical staff faces the difficult decision whether to con-
tinue treatments, replacing one or more vital functions, and so
on.
Practically, chronic critical illness may be considered as the
result of a previous decision, made by the clinicians, when
caring for an acutely ill patient admitted to ICU. Thus, this is
probably the right moment in which, depending on the
patient’s condition, age and prognosis, professionals have to
debate the limitations of therapies and the best setting for car-
ing. The difficult task that medical science will face in the
coming years will be to understand under what circumstances
the afflictions following intensive care may make sense (‘The
limit of every pain is an even greater pain’, Emil Cioran).
Conclusion
Recent advances in the intensive care setting have led to better
outcomes for patients with acute diseases, by applying a
number of techniques aimed at restoring their vital functions.
However, these medical advances have also led to an unex-
pected drawback: an increasingly larger population of patients
remain dependent on organ replacement techniques such as
mechanical ventilation. This condition, also known as chronic
critical illness, has a significant economic impact on the
healthcare system and requires a major effort in medical and
nursing care. The pathophysiological features of the condition
remain partially unclear, and at present, no specific treatment is
available, although a number of measures applied on ICU
admission may reduce its incidence. The challenge for the
coming years is to identify the risk factors and mechanisms
leading to the progression of an acute disease into chronic
critical illness, aiming at reducing its occurrence.
Funding disclosure
The authors have no financial involvement with any organiza-
tion or entity with a financial interest in competition with the
subject, matter or materials discussed in the manuscript.
Address
Respiratory Diseases Clinic, Policlinico di Modena, via del
Pozzo, 71, 41124 Modena, Italy (A. Marchioni, R. Fantini,
F. Antenora, E. Clini, L. Fabbri).
Correspondence to: Dr Alessandro Marchioni, Policlinico di
Modena, via del Pozzo, 71, 41124 Modena, Italy. Tel.: +39
0594225859; fax: +39 0594224231; email: marchioni.alessan-
dro@unimore.it
Received 19 July 2015; accepted 3 October 2015
References
1 Rosengart MR. Critical care medicine: landmarks and legends. Surg
Clin North Am 2006;86:1305–21.
2 Berthelsen PG, Cronqvist M. The first intensive care unit in the
world: Copenhagen 1953. Acta Anaesthesiol Scand 2003;47:1190–5.
3 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B.
Epidemiology of multimorbidity and implications for health care,
research, and medical education: a cross-sectional study. Lancet
2012;380:37–43.
4 Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-
specific mortality in 187 countries, 1970-2010: a systematic analysis
for the Global Burden of Disease Study 2010. Lancet 2012;380:2071–
94.
5 Girard K, Raffin TA. The chronically critically ill: to save or let die?
Respir Care 1985;30:339–47.
6 Carson SS. Definitions and epidemiology of the chronically critically
ill. Respir Care 2012;57:848–56; discussion 56-8.
7 MacIntyre NR, Epstein SK, Carson S, Scheinhorn D, Christopher K,
Muldoon S. Management of patients requiring prolonged
mechanical ventilation: report of a NAMDRC consensus conference.
Chest 2005;128:3937–54.
8 Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. Am
J Respir Crit Care Med 2010;182:446–54.
9 Engoren M, Arslanian-Engoren C, Fenn-Buderer N. Hospital and
long-term outcome after tracheostomy for respiratory failure. Chest
2004;125:220–7.
10 Carson SS, Garrett J, Hanson LC, Lanier J, Govert J, Brake MC
et al. A prognostic model for one-year mortality in patients
requiring prolonged mechanical ventilation. Crit Care Med
2008;36:2061–9.
11 Scheinhorn DJ, Hassenpflug MS, Votto JJ, Chao DC, Epstein SK,
Doig GS et al. Post-ICU mechanical ventilation at 23 long-term care
hospitals: a multicenter outcomes study. Chest 2007;131:85–93.
12 Cox CE, Carson SS, Lindquist JH, Olsen MK, Govert JA, Chelluri L;
Quality of Life After Mechanical Ventilation in the Aged (QOL-MV)
Investigators. Differences in one-year health outcomes and resource
utilization by definition of prolonged mechanical ventilation: a
prospective cohort study. Crit Care 2007;11:R9.
13 Stoller JK, Xu M, Mascha E, Rice R. Long-term outcomes for patients
discharged from a long-term hospital-based weaning unit. Chest
2003;124:1892–9.
14 Cox CE. Persistent systemic inflammation in chronic critical illness.
Respir Care 2012;57:859–64; discussion 64-6.
15 Meduri GU, Headley S, Kohler G, et al. Persistent elevation of
inflammatory cytokines predicts a poor outcome in ARDS. Plasma
IL-1 beta and IL-6 levels are consistent and efficient predictors of
outcome over time. Chest 1995;107:1062–73.
16 Kale SS, Yende S. Effects of aging on inflammation and hemostasis
through the continuum of critical illness. Aging Dis 2011;2:501–11.
17 Fullerton JN, O’Brien AJ, Gilroy DW. Pathways mediating
resolution of inflammation: when enough is too much. J Pathol
2013;231:8–20.
18 Nathan C, Ding A. Nonresolving inflammation. Cell
2010;140:871–82.
European Journal of Clinical Investigation 7
CHRONIC CRITICAL ILLNESS
19 Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis:
a novel understanding of the disorder and a new therapeutic
approach. Lancet Infect Dis 2013;13:260–8.
20 Hotchkiss RS, Monneret G, Payen D. Sepsis-induced
immunosuppression: from cellular dysfunctions to immunotherapy.
Nat Rev Immunol 2013;13:862–74.
21 Boonen E, Van den Berghe G. Endocrine responses to critical illness:
novel insights and therapeutic implications. J Clin Endocrinol Metab
2014;99:1569–82.
22 Prigent H, Maxime V, Annane D. Science review: mechanisms of
impaired adrenal function in sepsis and molecular actions of
glucocorticoids. Crit Care 2004;8:243–52.
23 Marik PE. Critical illness-related corticosteroid insufficiency. Chest
2009;135:181–93.
24 Beishuizen A, Thijs LG. The immunoneuroendocrine axis in critical
illness: beneficial adaptation or neuroendocrine exhaustion? Curr
Opin Crit Care 2004;10:461–7.
25 Boonen E, Vervenne H, Meersseman P, et al. Reduced cortisol
metabolism during critical illness. N Engl J Med 2013;368:1477–88.
26 Dungan KM, Braithwaite SS, Preiser JC. Stress hyperglycaemia.
Lancet 2009;373:1798–807.
27 Krinsley JS. Glycemic control in the critically ill - 3 domains and
diabetic status means one size does not fit all!. Crit Care 2013;17:131.
28 Schulman RC, Mechanick J. Metabolic and nutrition support in the
chronic critical illness syndrome. Respir Care 2012;57:958–77.
29 Chang HR, Bistrian B. The role of cytokines in the catabolic
consequences of infection and injury. J Parenter Enteral Nutr
1998;22:156–66.
30 Fuhrman MP, Charney P, Mueller CM. Hepatic proteins and
nutrition assessment. J Am Diet Assoc 2004;104:1258–64.
31 Ziegler TR. Parenteral nutrition in the critically ill patient. N Engl J
Med 2009;361:1088–97.
32 Deane A, Chapman MJ, Fraser RJ, Horowitz M. Bench-to-bedside
review:the gut as an endocrine organ in the critically ill. Crit Care
2010;14:228.
33 Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV
inhibition with MK0431 improves islet graft survival in diabetic
NOD mice partially via T-cell modulation. Diabetes 2009;58:641–51.
34 Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like
peptide-1 receptor signalling selectively regulates murine
lymphocyte proliferation and maintenance of peripheral regulatory
T cell. Diabetologia 2010;53:730–40.
35 Chatila TA. Regulatory T cells: key players in tolerance and
autoimmunity. Endocrinol Metab Clin North Am 2009;38:265–72.
36 Bakiner O, Bozkirli E, Giray S, Arlier Z, Kozanoglu I, Sezgin N et al.
Impact of early versus late enteral nutrition on cell mediated
immunity and its relationship with glucagon like peptide-1 in
intensive care unit patients: a prospective study. Crit Care 2013;17:
R123.
37 Girard DT. Brain dysfunction in patients with chronic critical illness.
Resp Care 2012;57:947–55.
38 Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE jr,
Inouye SK et al. Delirium as a predictor of mortality in mechanically
ventilated patients in the intensive care unit. JAMA 2004;291:1753–
62.
39 Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH.
Days of delirium are associated with 1-year mortality in an older
intensive care unit population. Am J Respir Crit Care Med
2009;180:1092–7.
40 Shehabi Y, Riker RR, Bokesch PM, Wisemandle W, Shintani A, Ely
EW. Delirium duration and mortality in lightly sedated,
mechanically ventilated intensive care patients. Crit Care Med
2010;38:2311–8.
41 Girard TD, Jackson JC, Pandharipande PP, Pun BT, Thompson JL,
Shintani AK et al. Delirium as a predictor of long-term cognitive
impairment in survivors of critical illness. Crit Care Med
2010;38:1513–20.
42 Nelson JE, Tandon N, Mercado AF, Camhi SL, Ely EW, Morrison RS.
Brain dysfunction:another burden for the chronically critically ill.
Arch Intern Med 2006;166:1993–9.
43 Scheinhorn DJ, Hassenpflug MS, Votto JJ, Chao DC,
Epstein SK, Doig GS et al. Ventilator-dependent survivors of
catastrophic illness transferred to 23 long-term care hospitals for
weaning from prolonged mechanical ventilation. Chest
2007;131:76–84.
44 Ceriana P, Fanfulla F, Mazzacane F, Santoro C, Nava S. Delirium in
patients admitted to a step-down unit: analysis of incidence and risk
factors. J Crit Care 2010;25:136–43.
45 Jubran A, Lawm G, Kelly J, Duffner LA, Grungor G, Collins EG et al.
Depressive disorders during weaning from prolonged mechanical
ventilation. Intensive Care Med 2010;36:828–35.
46 Unroe M, Kahan JM, Carson SS, Govert JA, Martinu T, Sathy SJ et al.
One-year trajectories of care and resource utilization for recipients of
prolonged mechanical ventilation: a cohort study. Ann Intern Med
2010;152:167–75.
47 Nelson JE, Mercado AF, Camhi SL, Tandon N, Wallenstein S,
August GI et al. Communication about chronic critical illness. Arch
Intern Med 2007;167:2509–15.
48 Hope AA, Morrison RS, Du Q, Wallenstein S, Nelson JE. Risk factors
for long-tem brian dysfunction after chronic critical illness. Ann Am
Thorac Soc 2013;10:315–23.
49 Trzepacz PT. Update on neuropathogenesis of delirium. Dement
Geriatr Cogn Disord 1999;10:330–4.
50 Girard TD, Pandharipande PP, Ely EW. Delirium in intensive care
unit. Crit Care 2008;12(Suppl 3):S3.
51 Papadopoulos MC, Lamb FJ, Moss RF, Davies DC, Tighe D, Bennett
ED. Faecal peritonitis causes oedema and neuronal injury in pig
cerebral cortex. Clin Sci 1999;96:461–6.
52 Van Der Mast RC. Pathophysiology of delirium. J Geriatr Psychiatry
Neurol 1998;11:138–45.
53 Hughes CG, Morandi A, Girard TD, Riedel B, Thompson JL,
Shintani AK et al. Association between endothelial dysfunction and
acute brain dysfunction during critical illness. Anesthesiology
2013;118:631–9.
54 Wurtman RJ, Hefti F, Melamed E. Precursor control of
neurotrasmitter synthesis. Pharmacol Rev 1980;32:315–35.
55 Pandharipande P, Cotton BA, Shintani A, Thompson J, Pun BT,
Morris JA Jr et al. Prevalence and risk factors for development of
delirium in surgical and trauma intensive care unit patients. J
Trauma 2008;65:34–41.
56 Schweickert WD, Hall J. ICU-acquired weakness. Chest
2007;131:1541–9.
57 Batt J, dos Santos CC, Cameron JI, Herridge MS. Intensive care unit-
acquired weakness: clinical phenotypes and molecular mechanisms.
Am J Respir Crit Care Med 2013;187:238–46.
58 Fenzi F, Latronico N, Refatti N, Rizzuto N. Enhanced expression of
E-selectin on the vascular endothelium of peripheral nerve in
critically ill patients with neuromuscular disorders. Acta Neuropathol
2003;106:75–82.
59 Sandri M. Protein breakdown in muscle wasting: role of autophagy-
lysosome and ubiquitin-proteasome. Int J Biochem Cell Biol
2013;45:2121–9.
8 ª 2015 Stichting European Society for Clinical Investigation Journal Foundation
A. MARCHIONI ET AL. www.ejci-online.com
60 Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, Sandri M. Mechanisms
regulating skeletal muscle growth and atrophy. FEBS J
2013;280:4294–314.
61 Masiero E, Agatea L, Mammucari C, Blaauw B, Loro E, Komatsu M
et al. Autophagy is required to maintain muscle mass. Cell Metab
2009;10:507–15.
62 Latronico N, Fenzi F, Recupero D, Guarneri B, Tomelleri G, Tonin P
et al. Critical illness myopathy and neuropathy. Lancet
1996;347:1579–82.
63 Takala J, Ruokonen E, Webster NR, et al. Increased mortality
associated with growth hormone treatment in critically ill adults. N
Engl J Med 1999;341:785–92.
64 Van den Berghe G, Baxter RC, Weekers F, et al. The combined
administration of GH-releasing peptide-2 (GHRP-2), TRH and
GnRH to men with prolonged critical illness evokes superior
endocrine and metabolic effects compared to treatment with GHRP-
2 alone. Clin Endocrinol (Oxf) 2002;56:655–69.
65 Ranieri VM, Suter PM, Tortorella C, et al. Effect of mechanical
ventilation on inflammatory mediators in patients with acute
respiratory distress syndrome: a randomized controlled trial. JAMA
1999;282:54–61.
66 Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical
and occupational therapy in mechanically ventilated, critically
ill patients: a randomised controlled trial. Lancet 2009;373:
1874–82.
67 Winkelman C, Higgins PA, Chen YJ, Levine AD. Cytokines in
chronically critically ill patients after activity and rest. Biol Res Nurs
2007;8:261–71.
68 Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin
therapy in the medical ICU. N Engl J Med 2006;354:449–61.
69 van den Berghe G, Wouters P, Weekers F, et al. Intensive
insulin therapy in critically ill patients. N Engl J Med
2001;345:1359–67.
70 Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional
glucose control in critically ill patients. N Engl J Med 2009;360:1283–
97.
71 Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of
diaphragm fibers in mechanically ventilated humans. N Engl J Med
2008;358:1327–35.
72 Jaber S, Petrof BJ, Jung B, et al. Rapidly progressive diaphragmatic
weakness and injury during mechanical ventilation in humans. Am J
Respir Crit Care Med 2011;183:364–71.
73 Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of a paired
sedation and ventilator weaning protocol for mechanically ventilated
patients in intensive care (Awakening andBreathingControlled trial):
a randomised controlled trial. Lancet 2008;371:126–34.
74 Kattelmann KK, Hise M, Russell M, Charney P, Stokes M, Compher
C. Preliminary evidence for a medical nutrition therapy protocol:
enteral feedings for critically ill patients. J Am Diet Assoc
2006;106:1226–41.
75 McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts P,
Taylor B et al. Guidelines for the Provision and Assessment of
Nutrition Support Therapy in the Adult Critically Ill Patient: Society
of Critical Care Medicine (SCCM) and American Society for
Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter
Enteral Nutr 2009;33:277–316.
76 Casaer MP, Ziegler TR. Nutritional support in critical illness and
recovery. Lancet Diabetes Endocrinol 2015;3:734–745.
77 Rubinson L, Diette GB, Song X, Brower RG, Krishnan JA. Low
caloric intake is associated with nosocomial bloodstream infections
in patients in the medical intensive care unit. Crit Care Med
2004;32:350–7.
78 Barr J, Hecht M, Flavin KE, Khorana A, Gould MK. Outcomes in
critically ill patients before and after the implementation of an
evidence-based nutritional management protocol. Chest
2004;124:1446–57.
79 Berger MM, Chiolero RL. Hypocaloric feeding: pros and cons. Curr
Opin Crit Care 2007;13:180–6.
80 Pandharipande P, Shintani A, Peterson J, Pun BT, Wilkinson GR,
Dittus RS et al. Lorazepam is an independent risk factor for
transitioning to delirium in intensive care unit patients.
Anesthesiology 2006;104:21–6.
81 Milbrandt EB, Kersten A, Kong L, Weissfeld LA, Clermont G, Fink
MP et al.Haloperidol use is associated with lower hospital mortality
in mechanically ventilated patients. Crit Care Med 2005;33:226–9.
82 Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs
haloperidol: treating delirium in a critical care setting. Intensive Care
Med 2004;30:444–9.
European Journal of Clinical Investigation 9
CHRONIC CRITICAL ILLNESS
